Breast cancer is the second leading cause of cancer-related deaths in women in the United States. Despite the increase in survival with trastuzumab in the adjuvant setting, up to 26% of patients with early-stage HER2+ breast cancer experience disease recurrence within 5 to 8 years. The interim analysis after 5 years of follow-up in the ExteNET trial is presented.
Adherence to prescribed therapy is pivotal in cancer treatment. To ensure that patients receive the full benefit of their prescribed therapy, nurses and nurse practitioners play a critical role in identifying adverse events and implementing effective interventions that balance efficacy and tolerability.
Results 31 - 40 of 154